Mylan Inc. is now selling a generic version of Pfizer Inc.'s overactive bladder drug Detrol.
The company said it started shipping its generic after receiving approval from the Food and Drug Administration. It said U.S. sales of Detrol, or tolterodine, totaled $61.5 million over the year ended Sept. 30.
Mylan plans to start selling a generic version of Detrol LA, a long-acting version of the drug, in early 2014 as part of an agreement with Pfizer. Annual U.S. sales of Detrol LA are around $600 million.
Release Date: November 29, 2012
Source: The Associated Press